{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-020699","form_type":"8-K","ticker":"FDMT","cik":"0001650648","company_name":"4D Molecular Therapeutics, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.841045+00:00","generated_at":"2026-06-15T04:14:26.208483+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"4DMT reports Q1 net loss $28.7M; cash runway into H1 2026 after $129M offering","bullets":["Net loss $28.7M for Q1 2023 vs $26.3M in Q1 2022; R&D expenses $22.4M.","Cash, equivalents and marketable securities $202M as of March 31, 2023; plus $129M net from May 2023 offering.","Positive interim data from 4D-150 Phase 1/2 PRISM trial for wet AMD: 100% injection-free at 36 weeks in 3E10 cohort.","Acquired worldwide rights to sCFH from Aevitas for 4D-175 (geographic atrophy) candidate.","Enrollment of Phase 2 dose expansion for 4D-150 expected to complete Q3 2023; initial data H1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-020699","json":"https://secwatch.observer/filing/0000950170-23-020699.json","markdown":"https://secwatch.observer/filing/0000950170-23-020699.md","text":"https://secwatch.observer/filing/0000950170-23-020699.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650648/000095017023020699/0000950170-23-020699-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650648/000095017023020699/fdmt-20230510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:14:26.208483+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3388a057bbf2e8d4f3bb6de952576c7c246fb208","claim":"4D Molecular Therapeutics, Inc. reported three months ended March 31, 2023 results: net income $28.7 million.","evidence_excerpt":"Net loss was $28.7 million for the quarter ended March 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1650648/000095017023020699/0000950170-23-020699-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2023"},{"label":"Net income","value":"$28.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}